Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
90.08%
Net Margin
91.52%
Efficiency Metrics
Revenue per Expense Ratio
10.08
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
23.92%
Income Tax Rate
0.00%
EPS
1.0500000000
Balance Sheet Analysis
Current Ratio
3.66
Cash Ratio
2.15
Working Capital
$3.91M
Debt to Equity
0.36
Debt to Assets
26.36%
Equity Ratio
73.26%
Cash Flow Analysis
Operating Cash Flow Ratio
44.21%
Free Cash Flow Ratio
44.21%
CapEx to Revenue
0.00%
Dividends Paid
$9.54M
Stock Buybacks
No buybacks
Total Shareholder Returns
$9.54M
Cash Position Change
-49.20%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 1.52%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
150.38%
Net Income
145.51%
EPS
145.65%
Operating Income
147.63%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
477.84%
Operating Cash Flow
173.30%
Free Cash Flow
173.30%
Balance Sheet Health
Assets
-8.54%
Debt
-29.14%
Book Value per Share
2.15%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
1.52%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
14.93%
5Y Revenue/Share
264.41%
3Y Dividend/Share
1.80%
5Y Dividend/Share
2.42%